# OnCo record paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019" ;
  schema:name "Potentially Curable Pancreatic Adenocarcinoma: ASCO Clinical Practice Guideline Update"@en ;
  schema:description "The 2019 American guideline update that made six months of modified FOLFIRINOX the preferred chemotherapy after pancreatic cancer surgery for patients fit enough to take it, on the strength of a single trial."@en ;
  schema:url <https://onco.cc/key-papers/paper-asco-potentially-curable-pancreatic-guideline-update-jco-2019/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1200/JCO.19.00946>, <https://pubmed.ncbi.nlm.nih.gov/31180816/> ;
  onco:tag "pancreatic-evidence" ;
  schema:sameAs <https://doi.org/10.1200/JCO.19.00946> ;
  schema:datePublished "2019"^^xsd:gYear ;
  schema:author "Khorana AA, McKernin SE, Berlin J, et al." ;
  onco:related <https://onco.cc/key-papers/paper-prodige-24-adjuvant-mfolfirinox-pancreatic-nejm-2018/> ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/resectable-pdac/> ;
  onco:drugs <https://onco.cc/drugs/folfirinox/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/capecitabine/> ;
  onco:institutions <https://onco.cc/institutions/asco/> ;
  onco:terms <https://onco.cc/terms/neoadjuvant-adjuvant/> ;
  onco:trials <https://onco.cc/trials/prodige-24/> ;
  onco:journals <https://onco.cc/journals/jco/> .